The role of lenalidomide in the management of myelodysplasia with del 5q

British Journal of Haematology

Volumn 140, Issue 3, 2008, Pages 267-278

  Kelaidi, Charikleia ^a   Eclache, Virginie ^a   Fenaux, Pierre ^a  

^a UNIVERSITÉ PARIS 13   (France)

Author keywords

5q; Lenalidomide; Myelodysplastic syndromes

Indexed keywords

CYTARABINE; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; LENALIDOMIDE; VASCULOTROPIN RECEPTOR;

ALLOGENIC BONE MARROW TRANSPLANTATION; BONE MARROW SUPPRESSION; CHROMOSOME 5Q; COST EFFECTIVENESS ANALYSIS; CYTOGENETICS; DEEP VEIN THROMBOSIS; DIARRHEA; ERYTHROCYTE TRANSFUSION; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE DELETION; GENE EXPRESSION REGULATION; GENE LOCATION; HUMAN; HYPOTHYROIDISM; MEGAKARYOPOIESIS; MYELODYSPLASIA; NEUTROPENIA; PRIORITY JOURNAL; PRURITUS; RASH; RBM22 GENE; REVIEW; SEPSIS; SURVIVAL; THROMBOCYTOPENIA; THROMBOCYTOSIS;

ANEMIA, REFRACTORY; ANTINEOPLASTIC AGENTS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 5; CYTOGENETICS; HUMANS; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; THALIDOMIDE; TREATMENT OUTCOME;

EID: 38349113462     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2007.06910.x     Document Type: Review

References (69)

1. Ades, L., Mohamed, H., Vassilief, D., Berger, E., Slama, B., Vey, N., Delarue, R., Beyne-Rauzy, O., Guerci, A., Cheze, S., Thomas, X., Stamatoullas, A., Gardembas, M., Bauduer, F., Kolb, A., Chaury, M.C., Legros, L., Damaj, G., Hamza, F., Vaultier, S., Dreyfus, F. Fenaux, P. (2005) Is there a role for ATRA in combination to EPO in lower risk myelodysplastic syndromes? Preliminary results of a phase II study. Blood, 106 (Suppl. 1 712a.
2. Aul, C., Runde, V. Gatterman, N. (1993) All-trans retinoic acid in patients with myelodysplastic syndromes: results of a pilot study. Blood, 82, 2967 2974.
3. Bartlett, J.B., Dredge, K. Dalgleish, A.G. (2004) The evolution of thalidomide and its ImiD derivatives as anticancer agents. Nature Reviews Cancer, 4, 314 322.
4. Bigoni, R., Cuneo, A., Milani, R., Cavazzini, F., Bardi, A., Roberti, M.G., Agostini, P., della Porta, M., Specchia, G., Rigolin, G.M. Castoldi, G. (2001) Multilineage involvement in the 5q- syndrome: a fluorescent in situ hybridization study on bone marrow smears. Haematologica, 86, 375 381.
5. Boultwood, J. Wainscoat, J. (2006) Molecular pathogenesis of the myelodysplastic syndromes, including the 5q- syndrome. Hematology (EHA Educ Program), 2, 69 74.
6. Boultwood, J., Lewis, S. Wainscoat, J.S. (1994) The 5q-syndrome. Blood, 84, 3253 3260.
7. Boultwood, J., Fidler, C., Strickson, A.J., Watkins, F., Gama, S., Kearney, L., Tosi, S., Kasprzyk, A., Cheng, J.F., Jaju, R.J. Wainscoat, J.S. (2002) Narrowing and genomic annotation of the commonly deleted region of the 5q- syndrome. Blood, 99, 4638 4641.
8. Bouscary, D., Legros, L., Tulliez, M., Dubois, S., Mahe, B., Beyne-Rauzy, O., Quarre, M.-C., Vassilief, D., Varet, B., Aouba, A., Gardembas, M., Giraudier, S., Guerci, A., Rousselot, P., Gaillard, F., Moreau, A., Rousselet, M.-C., Ifrah, N., Fenaux, P. Dreyfus, F. for The Groupe Francais des Myelodysplasies (GFM) (2005) A non-randomised dose-escalating phase II study of thalidomide for the treatment of patients with low-risk myelodysplastic syndromes: the Thal-SMD-2000 trial of the Groupe Francais des Myelodysplasies. British Journal of Haematology, 131, 609 618.
9. Buesche, G., Dieck, S., Giagounidis, A., Bock, O., Wilkens, L., Schlegelberger, B., Knight, R., Bennett, J., Aul, C. Kreipe, H.H. (2005) Anti-angiogenic in vivo effect of lenalidomide (CC-5013) in myelodysplastic syndrome with del(5q) chromosome abnormality and its relation to the course of disease. Blood, 106 (Suppl. 1 372a.
10. Casadevall, N., Durieux, P., Dubois, S., Hemery, F., Lepage, E., Quarre, M.C., Damaj, G., Giraudier, S., Guerci, A., Laurent, G., Dombret, H., Chomienne, C., Ribrag, V., Stamatoullas, A., Marie, J.-P., Vekhoff, A., Maloisel, F., Navarro, R., Dreyfus, F. Fenaux, P. (2004) Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial. Blood, 104, 321 327.
11. Cheson, B.D., Bennett, J.M., Kantarjian, H., Pinto, A., Schiffer, C.A., Nimer, S.D., Lowenberg, B., Beran, M., de Witte, T.M., Stone, R.M., Mittelman, M., Sanz, G.F., Wijermans, P.W., Gore, S. Greenberg, P.L. World Health Organization (WHO) International Working Group (2000) Report of an international working group to standardize response criteria for myelodysplastic. Blood, 96, 3671 3674.
12. Cheson, B.D., Greenberg, P.L., Bennett, J.M., Lowenberg, B., Wijermans, P.W., Nimer, S.D., Pinto, A., Beran, M., de Witte, T.M., Stone, R.M., Mittelman, M., Sanz, G.F., Gore, S.D., Schiffer, C.A. Kantarjian, H. (2006) Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood, 108, 419 425.
13. Estey, E.H., Thall, P.F., Cortes, J.E., Giles, F.J., O'Brien, S., Pierce, S.A., Wang, X., Kantarjian, H.M. Beran, M. (2001) Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts. Blood, 98, 3575 3583.
14. Fidler, C., Watkins, F., Bowen, D.T., Littlewood, T.J., Wainscoat, J.S. Boultwood, J. (2004) NRAS, FLT3 and TP53 mutations in patients with myelodysplastic syndrome and a del(5q). Haematologica, 89, 865 866.
15. Gandhi, A., Kang, J., Stirling, D. Schafer, P. (2007) Inhibition of cell proliferation by lenalidomide is associated with stimulation of EGR1 transcriptional activity in a chromosome 5 deleted Burkitt's lymphoma and multiple myeloma cell line. Haematologica, 92 (Suppl. 1 100.
16. Giagounidis, A.A., Germing, U., Haase, S., Hildebrandt, B., Schlegelberger, B., Schoch, C., Wilkens, L., Heinsch, M., Willems, H., Aivado, M. Aul, C. (2004) Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31. Leukemia, 18, 113 119.
17. Giagounidis, A.A., Haase, S., Germing, U., Schlegelberger, B., Wilkens, L., Busche, G., Kreipe, H.H., Wysk, J., Grips, K.H., Grabenhorst, U., Rothmann, F., Lubbert, M., Ganser, A., Aivado, M., Heinsch, M. Aul, C. (2005) Treatment of myelodysplastic syndrome with isolated del(5q) including bands q31-q33 with a combination of all-trans-retinoic acid and tocopherol-alpha: a phase II study. Annals of Hematology, 84, 389 394.
18. Giagounidis, A.A., Germing, U. Aul, C. (2006) Biological and prognostic significance of chromosome 5q deletions in myeloid malignancies. Clinical Cancer Research, 12, 5 10.
19. Giagounidis, A.A., Cazzola, M., Fenaux, P., Mufti, G., Muus, P., Platzbecker, U., Sanz, G., Cripe, L., Von Lilienfeld-Toal, M. Wells, R. (2007a) Management of haematological adverse events in MDS patients treated with lenalidomide. Leukemia Research, 31 (Suppl. 1 S121, P147.
20. Giagounidis, A.A., Cazzola, M., Fenaux, P., Mufti, G., Muus, P., Platzbecker, U., Sanz, G., Cripe, L., Von Lilienfeld-Toal, M. Wells, R. (2007b) Management of non-haematological adverse events in MDS patients treated with lenalidomide. Leukemia Research, 31 (Suppl. 1 S121 S122, P148.
21. Giagounidis, A.A., Haase, S., Heinsch, M., Gohring, G., Schlegelberger, B. Aul, C. (2007c) Lenalidomide in the context of complex karyotype or interrupted treatment: case reviews of del(5q)MDS patients with unexpected responses. Annals of Hematology, 86, 133 137.
22. Goss, T.F., Szende, A., Schaefer, C., Totten, P.J., Knight, R., Jädersten, M., Hellström-Lindberg, E. List, A. (2006) Cost effectiveness of lenalidomide in the treatment of transfusion-dependent myelodysplastic syndromes in the United States. Cancer Control, 13 (Suppl. 17 25.
23. Greenbeg, G.P., Cox, C., LeBeau, M.M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., Ohyashiki, K., Toyama, K., Aul, C., Mufti, G. Bennett, J. (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood, 89, 2079 2088.
24. Harris, N.L., Jaffe, E.S., Diebold, J., Flandrin, G., Muller-Hermelink, H.K., Vardiman, J., Lister, T.A. Bloomfield, C.D. (1999) World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee Meeting-Airlie House, Virginia, November 1997. Journal of Clinical Oncology, 17, 3835 3849.
25. Hellstrom-Lindberg, E., Ahlgren, T., Beguin, Y., Carlsson, M., Carneskog, J., Dahl, I.M., Dybedal, I., Grimfors, G., Kanter-Lewensohn, L., Linder, O., Luthman, M., Lofvenberg, E., Nilsson-Ehle, H., Samuelsson, J., Tangen, J.M., Winqvist, I., Oberg, G., Osterborg, A. Ost, A. (1998) Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. Blood, 92, 68 75.
26. Herry, A., Douet-Guilbert, N., Morel, F., Le Bris, M.J., Morice, P., Abgrall, J.F., Berthou, C. De Braekeleer, M. (2007) Evaluation of chromosome 5 aberrations in complex karyotypes of patients with myeloid disorders reveals their contribution to dicentric and tricentric chromosomes, resulting in the loss of critical 5q regions. Cancer Genetics and Cytogenetics, 175, 125 131.
27. Horrigan, S.K., Westbrook, C.A., Kim, A.H., Banerjee, M., Stock, W. Larson, R.A. (1996) Polymerase chain reaction-based diagnosis of del (5q) in acute myeloid leukemia and myelodysplastic syndrome identifies a minimal deletion interval. Blood, 88, 2665 2670.
28. Howe, R.B., Porwit-MacDonald, A., Wanat, R., Tehranchi, R. Hellstrom-Lindberg, E. (2004) The WHO classification of MDS does make a difference. Blood, 103, 3265 3270.
29. Ingram, W., Lea, N.C., Cervera, J., Germing, U., Fenaux, P., Cassinat, B., Kiladjian, J.J., Varkoniy, J., Antunovic, P., Westwood, N.P., Arno, M.J., Mohamedali, A., Gaken, J., Kontou, I., Czepulkowski, B.H., Twine, N.A., Tamaska, J., Csomer, J., Benedek, S., Gattermann, N., Zipperer, E., Giagounidis, A., Garcia-Casado, Z., Sanz, G. Mufti, G.J. (2006) The JAK2 V617F mutation identifies a subgroup of MDS patients with isolated deletion 5q and a proliferative bone marrow. Leukemia, 20, 1319 1321.
30. Jädersten, M., Montgomery, S.M., Dybedal, I., Porwit-MacDonald, A. Hellstrom-Lindberg, E. (2005) Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF. Blood, 106, 803 811.
31. Jädersten, M., Malcovati, L., Dybedal, I., Della Porta, M.G., Invernizzi, R., Montgomery, S.M., Pascutto, C., Porwit-MacDonald, A., Cazzola, M. Hellstrom-Lindberg, E. (2006) Treatment with erythropoietin and G-CSF improves survival in MDS patients with low transfusion need. Blood, 108 (Suppl. 1 158a.
32. Joslin, J.M., Fernald, A.A., Tennant, T.R., Davis, E.M., Kogan, S.C., Anastasi, J., Crispino, J.D. Le Beau, M.M. (2007) Haploinsufficiency of EGR1, a candidate gene in the del(5q), leads to the development of myeloid disorders. Blood, 110, 719 726.
33. Juneja, H.S., Jodhani, M., Gardner, F.H., Trevarthen, D. Schottstedt, M. (1994) Low-dose ARA-C consistently induces hematologic responses in the clinical 5q- syndrome. American Journal of Hematology, 46, 338 342.
34. Kantarjian, H., Issa, J.P., Rosenfeld, C.S., Bennett, J.M., Albitar, M., DiPersio, J., Klimek, V., Slack, J., de Castro, C., Ravandi, F., Helmer, III., R., Shen, L., Nimer, S.D., Leavitt, R., Raza, A. Saba, H. (2006) Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer, 106, 1794 1803.
35. Kelaidi, C., Park, S., Brechignac, S., Mannone, L., Vey, N., Dombret, H., Aljassem, L., Stamatoullas, A., Ades, L., Giraudier, S., de Botton, S., Mahe, B., Lepelley, P., Picard, F., Leroux, G., Daniel, M.T., Bouscary, D., Dreyfus, F. Fenaux, P. (2006) Treatment of myelodysplastic syndromes with del 5q before the lenalidomide era: the GFM experience. Blood, 108 (Suppl. 1 757a.
36. Knight, R., DeLap, R.J. Zeldis, J.B. (2006) Lenalidomide and venous thrombosis in multiple myeloma. The New England Journal of Medicine, 354, 2079 2080.
37. Lancet, J.E., List, A.F. Moscinski, L.C. (2007) Treatment of deletion 5q acute myeloid leukemia with lenalidomide. Leukemia, 21, 586 588.
38. Le Beau, M.M. (1992) Deletions of chromosome 5 in malignant myeloid disorders. Cancer Surveys, 15, 143 159.
39. + cells and uniparental disomy is not feature of 5q- syndrome. Blood, 108 (Suppl. 1 737a.
40. Lessard, M., Helias, C., Struski, S., Perrusson, N., Uettwiller, F., Mozziconacci, M.J., Lafage-Pochitaloff, M., Dastugue, N., Terre, C., Brizard, F., Cornillet-Lefebvre, P., Mugneret, F., Barin, C., Herry, A., Luquet, I., Desangles, F., Michaux, L., Verellen-Dumoulin, C., Perrot, C., Van den Akker, J., Lespinasse, J., Eclache, V. Berger, R. on behalf of the Groupe Francophone de Cytogénétique Hématologique (GFCH) (2007) Fluorescence in situ hybridization analysis of 100 hematopoietic disorders with chromosome 5 abnormalities: do de novo and therapy-related myelodysplastic syndrome-acute myeloid leukemia actually differ? Cancer Genetics and Cytogenetics, 176, 1 21.
41. Lewis, S., Oscier, D., Boultwood, J., Ross, F., Fitchett, M., Rack, K., Abrahamson, G., Buckle, V. Wainscoat, J.S. (1995) Hematological features of patients with myelodysplastic syndromes associated with chromosome 5q deletion. American Journal of Hematology, 49, 194 200.
42. List, A.F. (2007) Active treatment-improving outcomes in del 5q patients. Leukemia Research, 31 (Suppl. 1 S9.
43. List, A., Kurtin, S., Roe, D.J., Buresh, A., Mahadevan, D., Fuchs, D., Rimsza, L., Heaton, R., Knight, R. Zeldis, J.B. (2005) Efficacy of lenalidomide in myelodysplastic syndromes. The New England Journal of Medicine, 352, 549 557.
44. List, A., Dewald, G., Bennett, J., Giagounidis, A., Raza, A., Feldman, E., Powell, B., Greenberg, P., Thomas, D., Stone, R., Reeder, C., Wride, K., Patin, J., Schmidt, M., Zeldis, J. Knight, R. Myelodysplastic Syndrome-003 Study Investigators (2006) Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. The New England Journal of Medicine, 355, 1456 1465.
45. Littlewood, T.J., Bajetta, E., Nortier, J.W., Vercammen, E. Rapoport, B. Epoetin Alfa Study Group (2001) Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. Journal of Clinical Oncology, 19, 2865 2874.
46. Liu, T.X., Becker, M.W., Jelinek, J., Wu, W.S., Deng, M., Mikhalkevich, N., Hsu, K., Bloomfield, C.D., Stone, R.M., DeAngelo, D.J., Galinsky, I.A., Issa, J.P., Clarke, M.F. Look, A.T. (2007) Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation. Nature Medicine, 13, 78 83.
47. Lubbert, M., Wijermans, P., Kunzmann, R., Verhoef, G., Bosly, A., Ravoet, C., Andre, M. Ferrant, A. (2001) Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine. British Journal of Haematology, 114, 349 357.
48. Mannone, L., Gardin, C., Quarre, M.C., Bernard, J.F., Vassilieff, D., Ades, L., Park, S., Vaultier, S., Hamza, F., Beyne-Rauzy, M.O., Cheze, S., Giraudier, S., Agape, P., Legros, L., Voillat, L., Dreyfus, F. Fenaux, P. for the Groupe Francais des Myelodysplasies (GFM) (2006) High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study. British Journal of Haematology, 133, 513 519.
49. Mathew, P., Tefferi, A., Dewald, G.W., Goldberg, S.L., Su, J., Hoagland, H.C. Noel, P. (1993) The 5q- syndrome: a single-institution study of 43 consecutive patients. Blood, 81, 1040 1045.
50. Melchert, M., Williams, C. List, A. (2007a) Remitting activity of lenalidomide in treatment-induced myelodysplastic syndrome. Leukemia, 21, 1576 1578.
51. Melchert, M., Kale, V. List, A.F. (2007b) The role of lenalidomide in the treatment of patients with chromosome 5q deletion and other myelodysplastic syndromes. Current Opinion in Hematology, 14, 123 129.
52. Moreno-Aspitia, A., Colon-Otero, G., Hoering, A., Tefferi, A., Niedringhaus, R.D., Vukov, A., Li, C.Y., Menke, D.M., Geyer, S.M. Alberts, S.R. North Central Cancer Treatment Group (2006) Thalidomide therapy in adult patients with myelodysplastic syndrome. A North Central Cancer Treatment Group phase II trial. Cancer, 107, 767 772.
53. Negrin, R.S., Stein, R., Vardiman, J., Doherty, K., Cornwell, J., Krantz, S. Greenberg, P.L. (1993) Treatment of anemia in myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor in combination with erythropoietin. Blood, 82, 737 743.
54. Nilsson, L., Astrand-Grundstrom, I., Arvidsson, I., Jacobsson, B., Hellstrom-Lindberg, E., Hast, R. Jacobsen, S.E. (2000) Isolation and characterization of hematopoietic progenitor/stem cells in 5q-deleted myelodysplastic syndromes: evidence for involvement at the hematopoietic stem cell level. Blood, 96, 2012 2021.
55. Nilsson, L., Eden, P., Olsson, E., Mansson, R., Astrand-Grundström, I., Strömbeck, B., Theilgaard-Moench, K., Anderson, K., Hast, R., Hellström-Lindberg, E., Samuelsson, J., Bergh, G., Nerlov, C., Johansson, B., Sigvardsson, M., Borg, A. Jacobsen, S.E. (2007) The molecular signature of MDS stem cells supports a stem cell origin of 5q- myelodysplastic syndromes. Blood, doi:.
56. Nimer, S. (2006) Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q. Journal of Clinical Oncology, 24, 2576 2582.
57. Park, S., Kelaidi, C., Grabar, S., Beyne-Rauzy, O., Cheze, S., Bardet, V., Escoffre-Barbe, M., Ravoet, C., Ferrant, A., Vey, N., Dombret, H., Mahe, B., Mannone, L., Legros, L., Aljassem, L., Stamatoullas, A., Vassilief, D., Quarre, M.C., Ades, L., Andrieux, V., Giraudier, S., de Botton, S., Casadevall, N., Fenaux, P. Dreyfus, F. (2006) Prognostic factors and response duration in 419 MDS treated with erythropoietin ± GCSF: the GFM experience. Blood, 108 (Suppl. 1 158a.
58. Pedersen, B. Jensen, I.M. (1991) Clinical and prognostic implications of chromosome 5q deletions: 96 high resolution studied patients. Leukemia, 5, 566 573.
59. + cells in myelodysplastic syndromes: involvement of interferon stimulated genes and correlation to FAB subtype and karyotype. Blood, 108, 37 45.
60. Pellagatti, A., Jädersten, M., Forsblom, A.M., Cattan, H., Christensson, B., Emanuelsson, E., Merup, M., Nilsson, L., Samuelsson, J., Sander, B., Wainscoat, J., Boultwood, J. Hellström-Lindberg, E. (2007) Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients. Proceedings of the National Academy of Science of the United States of America, 104, 11406 11411.
61. Raza, A., Meyer, P., Dutt, D., Zorat, F., Lisak, L., Nascimben, F., du Randt, M., Kaspar, C., Goldberg, C., Loew, J., Dar, S., Gezer, S., Venugopal, P. Zeldis, J. (2001) Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood, 98, 958 965.
62. Stewart, B., Verdugo, M., Guthrie, K.A., Appelbaum, F. Deeg, H.J. (2003) Outcome following haematopoietic cell transplantation in patients with myelodysplasia and del (5q) karyotypes. British Journal of Haematology, 123, 879 885.
63. Strupp, C., Hildebrandt, B., Germing, U., Haas, R. Gattermann, N. (2003) Cytogenetic response to thalidomide treatment in three patients with myelodysplastic syndrome. Leukemia, 17, 1200 1202.
64. Tamburini, J., Elie, C., Vassilief, D., Quarre, M.C., Beyne-Rauzy, O., Gardembas, M., Aouba, A., Berthou, C., Sanhes, L., Guerci, A., Stamatoullas, A., Bauduer, F., Sotto, J.-J., Legros, L., Vaultier, S., Fenaux, P., Dreyfus, F. Bouscary, D. (2006) Low doses of thalidomide in low risk MDS with transfusion-dependent anemia: the GFM THAL-SMD-200 trial. Blood, 108 (Suppl. 1 756a.
65. Terpos, E., Mougiou, A., Kouraklis, A., Chatzivassili, A., Michalis, E., Giannakoulas, N., Manioudaki, E., Lazaridou, A., Bakaloudi, V., Protopappa, M., Liapi, D., Grouzi, E., Parharidou, A., Symeonidis, A., Kokkini, G., Laoutaris, N.P., Vaipoulos, G., Anagnostopoulos, N.I., Christakis, J., Meletis, J., Bourantas, K., Zoumbos, N.C., Yataganas, X. Viniou, N.A. for the Greek MDS Study Group (2002) Prolonged administration of erythropoietin increases erythroid response rate in myelodysplastic syndromes: a phase II trial in 281 patients. British Journal of Haematology, 118, 174 180.
66. Van den Berghe, H. Michaux, L. (1997) 5q-, twenty-five years later: a synopsis. Cancer Genetics and Cytogenetics, 94, 1 7.
67. Van den Berghe, H., Cassiman, J.J., David, G., Fryns, J.P., Michaux, J.L. Sokal, G. (1974) Distinct haematological disorder with deletion of long arm of no. 5 chromosome. Nature 251, 437 438.
68. Van den Berghe, H., Vermaelen, K., Mecucci, C., Barbieri, D. Tricot, G. (1985) The 5q-anomaly. Cancer Genetics and Cytogenetics, 17, 189 255.
69. Zhao, N., Stoffel, A., Wang, P.W., Eisenbart, J.D., Espinosa, III., R., Larson, R.A. Le Beau, M.M. (1997) Molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases to 1-1.5 Mb and preparation of a PAC-based physical map. Proceedings of the National Academy of Sciences of the United States of America, 94, 6948 6953.